IBDEI0EJ ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14534,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,14534,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,14534,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,14535,0)
 ;;=C92.40^^61^740^20
 ;;^UTILITY(U,$J,358.3,14535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14535,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,14535,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,14535,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,14536,0)
 ;;=D56.0^^61^740^21
 ;;^UTILITY(U,$J,358.3,14536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14536,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,14536,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,14536,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,14537,0)
 ;;=D63.1^^61^740^23
 ;;^UTILITY(U,$J,358.3,14537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14537,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,14537,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,14537,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,14538,0)
 ;;=D63.0^^61^740^24
 ;;^UTILITY(U,$J,358.3,14538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14538,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,14538,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,14538,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,14539,0)
 ;;=D63.8^^61^740^22
 ;;^UTILITY(U,$J,358.3,14539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14539,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,14539,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,14539,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,14540,0)
 ;;=C22.3^^61^740^26
 ;;^UTILITY(U,$J,358.3,14540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14540,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,14540,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,14540,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,14541,0)
 ;;=D61.9^^61^740^27
 ;;^UTILITY(U,$J,358.3,14541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14541,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,14541,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,14541,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,14542,0)
 ;;=D56.1^^61^740^29
 ;;^UTILITY(U,$J,358.3,14542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14542,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,14542,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,14542,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,14543,0)
 ;;=C83.79^^61^740^31
 ;;^UTILITY(U,$J,358.3,14543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14543,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14543,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,14543,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,14544,0)
 ;;=C83.70^^61^740^32
 ;;^UTILITY(U,$J,358.3,14544,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14544,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,14544,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,14544,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,14545,0)
 ;;=D09.0^^61^740^39
 ;;^UTILITY(U,$J,358.3,14545,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14545,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,14545,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,14545,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,14546,0)
 ;;=D06.9^^61^740^40
 ;;^UTILITY(U,$J,358.3,14546,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14546,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,14546,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,14546,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,14547,0)
 ;;=D06.0^^61^740^42
 ;;^UTILITY(U,$J,358.3,14547,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14547,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,14547,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,14547,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,14548,0)
 ;;=D06.1^^61^740^43
 ;;^UTILITY(U,$J,358.3,14548,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14548,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,14548,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,14548,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,14549,0)
 ;;=D06.7^^61^740^41
 ;;^UTILITY(U,$J,358.3,14549,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14549,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,14549,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,14549,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,14550,0)
 ;;=D04.9^^61^740^44
 ;;^UTILITY(U,$J,358.3,14550,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14550,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,14550,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,14550,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,14551,0)
 ;;=C91.11^^61^740^47
 ;;^UTILITY(U,$J,358.3,14551,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14551,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,14551,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,14551,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,14552,0)
 ;;=C91.10^^61^740^48
 ;;^UTILITY(U,$J,358.3,14552,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14552,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,14552,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,14552,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,14553,0)
 ;;=C92.11^^61^740^49
 ;;^UTILITY(U,$J,358.3,14553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14553,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,14553,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,14553,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,14554,0)
 ;;=C92.10^^61^740^50
 ;;^UTILITY(U,$J,358.3,14554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14554,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,14554,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,14554,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,14555,0)
 ;;=D47.1^^61^740^51
 ;;^UTILITY(U,$J,358.3,14555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14555,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,14555,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,14555,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,14556,0)
 ;;=C82.69^^61^740^52
 ;;^UTILITY(U,$J,358.3,14556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14556,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14556,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,14556,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,14557,0)
 ;;=C82.60^^61^740^53
 ;;^UTILITY(U,$J,358.3,14557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14557,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,14557,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,14557,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,14558,0)
 ;;=D56.2^^61^740^54
 ;;^UTILITY(U,$J,358.3,14558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14558,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,14558,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,14558,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,14559,0)
 ;;=D75.9^^61^740^55
 ;;^UTILITY(U,$J,358.3,14559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14559,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,14559,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,14559,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,14560,0)
 ;;=D59.0^^61^740^58
 ;;^UTILITY(U,$J,358.3,14560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14560,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,14560,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,14560,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,14561,0)
 ;;=D59.2^^61^740^59
 ;;^UTILITY(U,$J,358.3,14561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14561,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,14561,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,14561,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,14562,0)
 ;;=R59.9^^61^740^62
